By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verastem, Inc. 

215 First Street
Suite 440
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-858-0338 Fax: n/a


Company News
Verastem (VSTM) Reports Second Quarter 2017 Financial Results 8/9/2017 7:27:11 AM
Verastem (VSTM) Publishes Scientific Data Highlighting Potential Role Of FAK Inhibition In Pancreatic And Breast Cancer 7/25/2017 10:23:11 AM
Verastem (VSTM) Names Julie B. Feder As Chief Financial Officer 7/12/2017 7:16:17 AM
Verastem (VSTM) Reports Phase II Long-Term Follow-Up Data For Duvelisib In Patients With Double-Refractory Follicular Lymphoma And Small Lymphocytic Lymphoma At The 22nd Congress Of The European Hematology Association 6/26/2017 6:06:54 AM
Verastem (VSTM) To Present Long-Term Follow-Up Data From The DYNAMO Study At The 14th International Conference On Malignant Lymphoma 6/8/2017 6:24:10 AM
Verastem (VSTM) Reports First Quarter 2017 Financial Results 5/11/2017 7:46:30 AM
Verastem (VSTM) Announces Long Term Follow-Up Data From The DYNAMO Study Selected For Oral Presentation At The 14th International Conference On Malignant Lymphoma 5/3/2017 6:49:09 AM
Verastem (VSTM) Appoints Eric K. Rowinsky To The Board Of Directors 5/2/2017 6:06:21 AM
Data On Verastem (VSTM)’s Focal Adhesion Kinase Inhibitor Defactinib Presented At The 2017 AACR Annual Meeting 4/3/2017 10:43:46 AM
Verastem (VSTM) Reports Year-End 2016 Financial Results 3/24/2017 6:32:16 AM